Reshma Kewalramani
2021
In 2021, Reshma Kewalramani earned a total compensation of $15.2M as CEO and President at Vertex Pharmaceuticals, a 67% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $3,016,570 |
|---|---|
| Salary | $1,221,923 |
| Stock Awards | $10,924,599 |
| Other | $35,764 |
| Total | $15,198,856 |
Kewalramani received $10.9M in stock awards, accounting for 72% of the total pay in 2021.
Kewalramani also received $3M in non-equity incentive plan, $1.2M in salary and $35.8K in other compensation.
Rankings
In 2021, Reshma Kewalramani's compensation ranked 525th out of 12,415 executives tracked by ExecPay. In other words, Kewalramani earned more than 95.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 525 out of 12,415 | 96th |
Division Manufacturing | 173 out of 5,508 | 97th |
Major group Chemicals And Allied Products | 53 out of 2,378 | 98th |
Industry group Drugs | 48 out of 2,099 | 98th |
Industry Pharmaceutical Preparations | 29 out of 1,549 | 98th |
Source: SEC filing on April 7, 2022.
Kewalramani's colleagues
We found four more compensation records of executives who worked with Reshma Kewalramani at Vertex Pharmaceuticals in 2021.